You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD20 lymphoid malignancies

Showing 1 - 25 of 4,449
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

Recruiting
  • Recurrent Acute Lymphoblastic Leukemia
  • +15 more
  • Anti-CD19/CD20/CD22 CAR T-Cells
  • +2 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Nov 4, 2022

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Huntsville, Bethesda (Ublituximab,

Terminated
  • Non-Hodgkins Lymphoma
  • +6 more
  • Huntsville, Alabama
  • +1 more
May 5, 2022

B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia Trial in Milwaukee (Dose Level -1: 0.75x10^6 cells/kg

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • B-cell Chronic Lymphocytic Leukemia
  • Dose Level -1: 0.75x10^6 cells/kg CAR20.19.22 cells
  • +3 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin and Froedtert Hospital
Jul 1, 2022

Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia Trial run by the NCI (Anti-cluster of differentiation 19

Terminated
Has Results
  • Lymphoma, B-Cell
  • +3 more
  • Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptors (CAR) and Anti-cluster of differentiation 20 (CD20)-CAR T cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2022

Relapsed and Refractory, Lymphoid Hematological Malignancies Trial in Hangzhou (CD20/CD22 dual Targeted CAR T-cells)

Recruiting
  • Relapsed and Refractory
  • Lymphoid Hematological Malignancies
  • CD20/CD22 dual Targeted CAR T-cells
  • Hangzhou, Zhejiang, China
    The First Hospital of Zhejiang Medical Colleage Zhejiang Univers
Aug 20, 2020

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • São Paulo, Brazil
    Hospital Israelita Albert Einstein
Jan 20, 2023

B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

Recruiting
  • B-cell Lymphoma
  • +5 more
  • Louisville, Kentucky
    Norton Cancer Institute
Jan 24, 2023

T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma Trial in Wuhan (Fludarabine +

Recruiting
  • T-Cell Lymphocytic Leukemia
  • +2 more
  • Fludarabine + Cyclophosphamide + CAR7-T Cells
  • Wuhan, Hubei, China
    Union Hospital, Huazhong University of Science and Technology
Mar 1, 2022

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia Trial in Cleveland (Fully human anti CD19 CAR-T

Recruiting
  • Non Hodgkin Lymphoma
  • +2 more
  • Fully human anti CD19 CAR-T Cell Dose
  • +2 more
  • Cleveland, Ohio
    University Hospitals Cleveland Medical Center, Case Comprehensiv
Oct 4, 2022

Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma Trial in Langfang (CD7CAR T cells)

Recruiting
  • Relapsed/Refractory, High Risk Hematologic Malignancies
  • T-ALL/Lymphoma
  • CD7CAR T cells
  • Langfang, Hebei, China
    Hebei Yanda Lu Daopei Hospital
Jun 30, 2022

Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • +5 more
  • La Jolla, California
  • +7 more
Aug 25, 2023

Lymphoma, Non-Hodgkin Trial (JNJ-87801493, JNJ-80948543, JNJ-75348780)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • (no location specified)
Nov 15, 2023

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Taipei (RPM

Terminated
  • B-cell Acute Lymphoblastic Leukemia
  • +7 more
  • RPM CD19-mbIL15-CAR-T cells
  • Taipei, Taiwan
    National Taiwan University Hospital
May 11, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies Trial in Hefei (T cell injection targeting CD7 chimeric

Recruiting
  • CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
  • T cell injection targeting CD7 chimeric antigen receptor
  • Hefei, Anhui, China
    PersonGen.Anke Cellular Therapeutice Co., Ltd.
Dec 24, 2021

AML, ALL, Lymphoid Malignancies Trial in Birmingham (Infusion of CD34 selected hematopoietic stem cells)

Not yet recruiting
  • AML
  • +5 more
  • Infusion of CD34 selected hematopoietic stem cells
  • Birmingham, Alabama
    University of Alabama at Birmingham
Sep 14, 2023

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma Trial in Taiyuan (CAR-T Autologous T cell injection)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • CAR-T Autologous T cell injection
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Dec 2, 2022

Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in Fairway, Houston (SC291)

Recruiting
  • Non Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Fairway, Kansas
  • +1 more
May 30, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
  • +4 more
  • Milwaukee, Wisconsin
    Medical College of Wisconsin
Sep 22, 2022

Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial in France, Germany, United States (Odronextamab multiple dose levels)

Recruiting
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Odronextamab multiple dose levels
  • Orange, California
  • +20 more
Dec 14, 2022

Anemia, B-Cell Prolymphocytic Leukemia, Grade 1 Follicular Lymphoma Trial in Portland (drug, other, biological)

Completed
  • Anemia
  • +13 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Apr 29, 2021